Introduction 42
Western diets containing meat have a larger negative impact on the environment 43 compared to plant-based diets. [1] [2] [3] [4] However, due to both social and personal reasons, many 44 consumers are resistant to reducing the amount of meat they eat. 2, 5, 6 To date, plant-based diets 45 have been limited to small, motivated populations, such as consumers who follow vegetarian or 46 vegan principles. [7] [8] [9] One potential way to catalyze widespread shift to more sustainable, plant-47 based diets is to create meat directly from plants that satisfies the tastes of meat consumers. 7,8,10 48 Achieving that goal would require products that recreate the sensory properties that people crave 49 in meat, including texture, mouthfeel, taste, smell, and cooking experience, based on an 50 understanding of the biochemical origins of meat sensory attributes. 51
An investigation of the molecular mechanisms underlying the unique flavors and aromas 52 of meat led to the discovery that heme is the critical catalyst of the chemical reactions that 53 transform simple biomolecules into the complex array of odorants and flavor molecules that 54 define the characteristic flavor profile of meat. 11 Heme is an iron-containing porphyrin ring that 55 exists as a protein co-factor in all branches of life and is essential for most biochemical processes 56 involving molecular oxygen. 12 Myoglobin and hemoglobin proteins from animal meat tissues 57 have been consumed throughout human history and represent an important source of dietary 58 iron. 13, 14 Plants contain symbiotic and non-symbiotic hemoglobin proteins, both of which share a 59 common ancestor with animal hemoglobins. 15 Symbiotic plant hemoglobins, also known as 60 leghemoglobins, are present in the root nodules of leguminous plants. 16 Leghemoglobin controls 61 bacterial strains were evaluated (Salmonella typhimurium (ST) TA98, TA100, TA1535 and 133 TA1537 and Escherichia coli (EC) WP2uvrA (Molecular Toxicology, Inc., Boone, NC)) 134 according to the plate incorporation and pre-incubation methods in both the presence and 135 absence of a metabolic activation system (S9 mix). Sterile water served as the negative control, 136 while five mutagens including sodium azide (NaN 3 ), ICR 191 acridine, daunomycin, methyl 137 methanesulfonate (MMS) and 2-aminoanthracene (2-AA) (Molecular Toxicology, Inc., Boone, 138 NC) were used as the positive controls. Water was also used as the solvent for the positive 139 controls except for 2-AA which was prepared in dimethyl sulfoxide (DMSO). The initial test 140 followed the plate incorporation method, in which the following materials were mixed and 141 poured over the surface of a minimal agar plate: 100 µL of the prepared test solutions, negative 142 (vehicle) control, or prepared positive control substance; 500 µL S9 mix or substitution buffer; 143 100 µL bacteria suspension (ST or EC); and 2000 µL overlay agar maintained at approximately 144 45 °C. 145
Plates were prepared in triplicate and uniquely identified. Appropriate sterility control 146 check plates (treated with critical components in the absence of bacteria) were included as a 147 standard procedural check. After pouring, plates were placed on a level surface until the agar 148 gelled, then inverted and incubated at 37 ± 2 °C until growth was adequate for enumeration 149 (approximately 65 ± 3 hours). 150
The confirmatory test employed the pre-incubation modification of the plate 151 incorporation test. The test or control substances, bacteria suspension, and S9 (or substitution 152 buffer) were incubated under agitation for approximately 30 minutes at approximately 37 ± 2 °C 153 prior to mixing with the overlay agar and pouring onto the minimal agar plates before proceeding 154 as described for the initial test. Following incubation, the revertant colonies were counted 155 manually and/or with the aid of a plate counter (Colony Plate Reader: Model Colony-Doc-It TM ). 156
To be considered valid, the background lawn for vehicle control plates had to appear slightly 157 hazy with abundant microscopic non-revertant bacterial colonies. The mean revertant colony 158 counts for each strain treated with the vehicle had to lie close to or within the expected range 159 taking into account the laboratory historical control range. For each experimental point, the 160 Mutation Factor (MF) was calculated by dividing the mean revertant colony count by the mean 161 revertant colony count for the corresponding concurrent vehicle control group. The results were 162 considered to be positive when the MF was increased at least by a factor of two for strains TA98, 163 TA100 and WP2 uvrA or by at least a factor of three for strains TA1535 and TA1537. In 164 addition, any increases had to be dose-related and/or reproducible, i.e., increases must be 165 obtained at more than one experimental point (at least one strain, more than one dose level, more 166 than one occasion or with different methodologies). 167 168
Chromosome Aberration Assay in Human Peripheral Blood Lymphocytes (HPBL) 169
The chromosomal aberration assay 42 was conducted at Eurofins Biopharma (Munich, 170 Germany) in compliance with the German GLP regulations according to 19b Abs. 1 171 chemikaliengesetz 43 and the protocol procedures described in the Term Tests for Genetic 172 Toxicity and OECD 473, In Vitro Mammalian Chromosome Aberration Test 39,44 and the 173 European Commission Regulation (EC) No.440/2008 B.10. 45 The study was conducted using 174 human peripheral blood lymphocytes (HPBL) in both the absence and presence of the 175 chemically-induced rat liver S9 metabolic activation system (Trinova Biochem, Giessen, 176 Germany). Peripheral blood lymphocytes were obtained from healthy non-smoking donors who 177 had no recent history of exposure to genotoxic chemicals and radiation. Peripheral blood 178 lymphocytes were cultured in complete medium (RPMI-1640 containing 15% heat inactivated 179 fetal bovine serum, 0.24 g/mL of phytohemagglutinin and 100 units penicillin and 100 µg/mL 180 streptomycin). The cultures were incubated under standard conditions (37 °C in a humidified 181 atmosphere of 5% CO 2 in air) for 48 hours. The cells were treated for periods of 4 or 24 hours in 182 the non-activated test system and for a period of 4 hours in the S9-activated test system. All cells 183 were harvested 24 hours after treatment initiation. Cyclophosphamide and ethylmethanesulfonate 184 (Sigma-Aldrich, MO) were evaluated as the concurrent positive controls for treatments with and 185 without S9, respectively. 186
In addition to the mitotic index determination, the proliferation index of selected samples 187 (negative control and high doses of LegH Prep) was calculated using the BrdU (5-bromo-2'-188 deoxyurindine) technique. The proliferation index was calculated using Equation 1 (where M1 is 189 the first generation, M2 is the second generation, and M3 is the third generation) based on the 190 number of cell divisions undertaken during the experiment. 191
(1) 193 194
14-Day Dietary Palatability and Range Finding Study in Rats 195
This study 46 Laboratories (Kingston, NY) and subsequently quarantined and acclimated to the PSL facilities 237 as described above. Eighty rats were selected for testing, using acceptance criteria described 238 above, and distributed into four groups with 10 males and 10 females per group (1 control group 239 per sex and 3 dietary dose levels per sex). The freeze-dried LegH Prep was administered in the 240
diet. 241
Prior to study initiation and again on study day 23, the eyes of all rats were examined by 242 focal illumination and indirect ophthalmoscopy. Clinical observations, food consumption, body 243 weight, and food efficiency were evaluated as described above. On study day 22, samples were 244 collected from all animals for hematology, serum chemistry and urinalysis evaluation. Blood 245 samples for hematology and serum chemistry were collected via sublingual bleeding under 246 isoflurane anesthesia. Approximately 500 µL of blood were collected in a pre-calibrated tube 247 containing K 2 EDTA for hematology assessments. The whole blood samples were stored under 248 refrigeration and shipped on cold packs. Approximately 1000 µL of blood were collected into a 249 tube containing no preservative for serum chemistry assessments. At terminal sacrifice, all 250 animals were euthanized by exsanguination from the abdominal aorta under isoflurane anesthesia 251 and blood was collected for evaluation of coagulation parameters. All clinical pathology samples 252 were sent to DuPont Haskell Global Centers for Health and Environmental Sciences (Newark, 253 DE) for analysis. All animals in the study were subjected to a full necropsy, which included 254 examination of the external surface of the body, all orifices, and the thoracic, abdominal and 255 cranial cavities and their contents. Tissues/organs representing systems were collected and 256 preserved in 10% Neutral Buffered Formalin with the exception of the eyes, testes and 257 epididymides, which were preserved in Davidson's fixative before transfer to ethanol. A subset 258 of tissues/organs were weighed wet as soon as possible after dissection to avoid drying 259 including: adrenal glands, kidneys, spleen, brain, liver, thymus, testes, epididymides, ovaries 260 with oviducts, uterus, and heart. The fixed tissues were trimmed, processed, embedded in 261 paraffin, sectioned with a microtome, placed on glass microscope slides, stained with 262 hematoxylin and eosin, and examined by light microscopy. Histological examination was 263 performed on the preserved organs and tissues of the animals from the vehicle control and high 264 dose groups (Groups 1, and 4, respectively), with the exception of the female reproductive 265 organs, which were evaluated for all dose levels. Slide preparation and histopathological 266 assessment was performed by a Board Certified Veterinary Pathologist at Histo-Scientific 267
Research Laboratories (HSRL) (Mount Jackson, VA). A pathology peer review was performed 268 by a Board Certified Veterinary Pathologist at Regan Path/Tox Services (Ashland, OH) for all 269 female reproductive tissues. 270
28-Day Investigative Study with a 14-Day Pre-Dosing Estrous Cycle Determination 272
A study was conducted at PSL (Dayton, NJ) 52 and the protocol was approved by the 273 IACUC of PSL. Adult CRL Sprague-Dawley CD® IGS female rats were purchased from 274
Charles River Laboratories and subsequently quarantined and acclimated at the PSL facilities as 275 described above. Sixty rats were selected for testing using the acceptance criteria described 276 above and animals were distributed into four groups with 15 females per group (1 control group 277 per sex and 3 dietary dose levels per sex). Freeze dried LegH Prep was administered in the diet. 278
The estrus cycle was evaluated daily by vaginal cytology for a period of 14 days prior to 279 administration of the test substance and for the last two weeks of the 28-day period of test 280 substance administration. Estrous cycle stage was not evaluated for the first two weeks of the 281 dosing period to avoid over-manipulating the animals. For each 14-day period, average estrus 282 cycle length was calculated for each animal and subsequently each group. Clinical observations, 283 food consumption, body weight, and food efficiency were evaluated as described above. All 284 animals were subjected to a full necropsy, which included examination of the external surface of 285 the body, all orifices, and the thoracic, abdominal and cranial cavities and their contents. Female 286 reproductive organs were collected and preserved in 10% Neutral Buffered Formalin. The 287 ovaries with oviducts and uterus were weighed wet as soon as possible after dissection to avoid 288 drying. Reproductive tissues were fixed and examined as described above. Estrous cycle stage 289 was recorded for all animals. Histological examination was performed on the preserved organs 290 and tissues for group 1 and group 4 animals. Slide preparation was performed by Histoserv Inc. 291 (Germantown, MD) and histopathological assessment was performed by a Board Certified 292 
Results

314
Bacterial Reverse Mutation Assay (Ames Test) 315
The objective of this test was to determine the mutagenic potential of LegH Prep using 316 histidine-requiring strains of S. typhimurium (TA98, TA100, TA1535 and TA1537) and a 317 tryptophan-requiring strain of E. coli (WP2 uvrA). LegH Prep was evaluated with and without an 318 exogenous metabolic activation (S9 mix) at levels of 23.384, 74, 233.84, 740, 2338.4, 7400, 319 23,384 and 74,000 µg/plate, which corresponded to 1.58, 5.0, 15.8, 50, 158, 500, 1580, and 5000 320 µg/plate of the characterizing component, LegH, with the high level being the standard limit for 321 this test. 322
The mean revertant colony counts for each strain treated with the vehicle were close to or 323 within the expected range, considering the laboratory historical control range and/or published 324 values. 60,61 The positive control substances caused the expected substantial increases in revertant 325 colony counts in both the absence and presence of S9 in each phase of the test, confirming the 326 sensitivity of the test and the activity of the S9 mix (Table 1) . No signs of precipitation or 327 contamination were noted throughout the study. Therefore, each phase of the test is considered 328 valid. 329 LegH Prep did not cause a positive increase in the mean number of revertant colonies per 330 plate with strains TA1535, TA1537, TA98, TA100 or WP2 uvrA in either the absence or 331 presence of S9 when using either the plate incorporation or the pre-incubation method ( Table 1) . 332 Therefore, LegH Prep was non-mutagenic in the bacterial reverse mutation assay. 333 334
Chromosome Aberration Assay in Human Peripheral Blood Lymphocytes (HPBL) 335
The objective of this in vitro assay was to evaluate the ability of LegH Prep to induce 336 structural or numerical (polyploid or endoreduplicated) chromosome aberrations in HPBL. 337 HPBL cells were exposed to LegH Prep for 4 hours in the presence or absence of S9 338 (Experiment 1) or for 24 hours in the absence of S9 (Experiment 2). In each experiment, 339 untreated and positive controls values were within the historical control range indicating that the 340 subject assay met the criteria for a valid test. 341
In accordance with OECD guidelines, Experiment 1 used the recommended 342 concentrations of 100-5000 µg/mL LegH, which corresponded to 148-74,000 µg/mL LegH Prep. 343
Mitotic index was evaluated first since decreased mitotic index can inhibit the ability to evaluate 344 chromosome aberrations. Although the mitotic index decreased to below 70% of the negative 345 control at high concentrations of LegH Prep without S9 metabolic activation, no such decrease in 346 the mitotic index was observed in the presence of S9 metabolic activation (Table 2) . No 347 significant difference in the proliferation index was observed in either condition (Table 3) . 348
Evaluation of chromosomal aberration tests using the mitotic index can be unreliable. 62 349 However, in all cases, the mitotic index remained above the 45% of control threshold that is 350 recommended for evaluation of structural and numerical chromosomal aberrations and no test 351 article precipitation was observed. In Experiment 1, no significant increase in cells with 352 structural or numerical chromosome aberrations was observed up to 5000 µg/mL LegH, which 353 was the maximum dose tested, both with and without S9 (Table 2) . 354
The increased incubation time of Experiment 2 resulted in precipitation of the test article 355 at concentrations of greater than or equal to 500 µg/mL LegH. Additionally, the mitotic index 356 values relative to the control decreased below the 45% percent threshold at concentrations 357 greater than 1000 µg/mL LegH. Therefore, only concentrations up to 1000 µg/mL LegH were 358 evaluated for chromosome aberrations. The proliferation index values for 500 and 1000 359 micrograms/plate were 1.23 (79% relative to control) and 1.12 (72% relative to control), 360 respectively (Table 3 ). This decrease was not a consequence of chromosome aberrations. In 361 Experiment 2, no significant increase in cells with structural or numerical chromosome 362 aberrations was observed up to 1000 µg/mL LegH, which was the maximum dose evaluated, 363 without metabolic activation (Table 2) . 
14-Day Dietary Palatability and Range Finding Study in Rats 379
A 14-day toxicology and palatability feeding study in rats 46 was performed to assess the 380 feasibility of oral administration of freeze-dried LegH Prep in the diet and to establish the dose 381 range for the subsequent 28-day study. The test article was administered in doses of 0, 3156, 382 6312, and 12,612 ppm (Groups 1-4, respectively) corresponding to active ingredient LegH 383 concentrations of 0, 125, 250 and 500 mg/kg/day. The calculated nominal dietary intake levels 384 were 134, 269, and 531 mg/kg/day for Group 2-4 male rats and 148, 296, and 592 mg/kg/day for 385
Group 2-4 female rats. The animals are considered to have received acceptable dose levels. 386
Mortality, Clinical Signs, Body Weight/Food Consumption 387
There were no mortalities during the course of the 14-day study. There were no clinical 388 observations attributed to administration of LegH Prep. In-life clinical signs included reported 389 discoloration of the urine in 6/6 Group 4 males and 5/6 Group 4 females on day 5. Due to its 390 single day occurrence, this observation is likely due to re-hydration of the test article by animal 391 urine, which would result in the formation of a red/brown color. Without a correlation to clinical 392 hematology or any other parameter, these findings are interpreted to be of no toxicological 393 significance. There were no changes in mean food consumption, mean food efficiency, mean 394 body weight, and mean daily body weight gain attributable to the administration of LegH Prep. 395
Pathology 396
There were no changes in hematology values attributable to the administration of LegH 397
Prep. There were no LegH Prep-related macroscopic or microscopic findings. Mean absolute and 398 relative organ-to-body weights for Group 2-4 were comparable to control group 1 throughout the 399 study. These results suggest that LegH Prep would be well tolerated in a study of longer 400 duration. 401 402
28-Day Dietary Feeding Study in Rats 403
A 28-day dietary feeding study in rats was performed to evaluate the potential subchronic 404 toxicity of LegH Prep following continuous exposure of the test substance in the diet. A no 405 observed adverse effect level (NOAEL) was sought for each sex. Due to the successful 406 palatability of 500 mg/kg/day LegH in the previous 14-day feeding study, the maximum dose 407 was increased to 750 mg/kg/day LegH. Administered doses of 0, 512, 1024 and 1536 mg/kg/day 408 of freeze-dried LegH Prep corresponded to 0, 250, 500 and 750 mg/kg/day of LegH, 409
respectively. The slight difference between in correlation between LegH Prep dose levels and 410
LegH concentrations compared to the previous 14-day study are due to the utilization of a 411 (Tables 4-6) . A statistically significant decrease (p < 0.01) in mean daily body 420 weight gain was observed in group 2 females on days 14-21 (Table 4 ). This decrease was 421 transient and was interpreted to have no toxicological relevance. Statistically significant 422 increases (p < 0.05-0.01) were observed for mean daily food consumption in Group 3 males on 423 days 7-14 and in Group 4 males on days 7-10, that were transient and without significant impact 424 on body weight, and were interpreted to be non-toxicologically relevant (Table 5 ). Mean food 425 efficiency for the treated female rats in Group 2-4 was generally comparable to the control 426
Group 1 values throughout the study, with the exception of statistically significant increases (p < 427 0.01) in Group 2 on Days 14-21 that were transient and without significant impact on body 428 weight and were interpreted to be non-toxicologically relevant. These small but significant 429 changes were all considered to be non-toxicologically relevant and non-test article dependent. 430
Pathology 431
There were to no test-substance-related changes in hematology parameters for male or 432 rats (Table 7) . Statically significant increase in red blood cell, hematocrit, and hemoglobin values 433 and absolute basophil counts for Group 2 females and decreased absolute reticulocyte counts in 434
Group 3 females were non-dose dependent and were interpreted to be within the expected 435 biological variation and therefore not toxicologically relevant and not test article dependent 436 (Table 7) . There were no test-substance-related changes in coagulation parameters for female 437 rats. A non-dose dependent increase in activated partial thromboplastin time (APPT) was 438 observed in Group 3 and 4 males. Due to its very slight magnitude and lack of correlating 439 pathological or clinical finding, this change is considered non-adverse. There were no test-440 substance-related changes in serum chemistry parameters for male rats (Table 8) . Alkaline 441 phosphatase (ALKP) was minimally decreased in a non-dose-dependent manner for Group 2 and 442 Group 4 females (Table 8 ). This minimal decrease was not correlated with concurrent clinical 443 pathology or histopathology changes and due to its limited clinical relevance is interpreted to 444 have no toxicological significance and was not test-article dependent. Other differences in serum 445 chemistry parameters that were statistically significant consisted of increased albumin and 446 potassium values in Group 3 males, decreased glucose and chloride in Groups 2 and 3 females, 447
increased globulin values in Group 3 females and increased calcium in Groups 2 and 3 females. 448
These were generally of small magnitude, lacked a response in a dose-dependent manner and are 449 interpreted to be within expected biological variation and considered to be of no toxicological 450 relevance and non-test-article-dependent. There were no test-substance-related changes in 451 urinalysis parameters for males or female rats. (Table 9 ) 452
There were no test-article-dependent effects observed during necropsy, organ weights, 453 macroscopic evaluation and microscopic evaluation in male and female rats, with a single 454 exception of a distinct estrous cycle stage distribution in the female rats. The estrous cycle 455 consists of four stages: proestrus, estrus, metestrus, and diestrous. Each stage has characteristic 456 reproductive organ weights and pathology. At study termination, Group 2 and 4 females had an 457 increased incidence of metestrus and a decreased incidence of estrus compared to Groups 1 and 458 3. Consistent with the estrous cycle stage distribution, Group 2 and 4 females also had decreased 459 presence of fluid-filled uteri and dilated uterine lumens and decreased uterine weights compared 460 to Group 1 and 3 females (Table 10-11). These decreases did not correlate with adverse 461 histopathological findings and are therefore interpreted to be non-adverse. The presence of both 462 new and old ovarian corpora lutea in females from all groups indicated that all females were 463 cycling normally. All other microscopic findings at the study day 29/30 time point were also 464 unrelated to administration of LegH Prep and can be observed in the age and strain of rats used 465 in this study. 63, 64 Although the differences in estrous cycle stage distribution between groups was 466 likely due sampling and assessing estrous cycle distribution on a single day, rather than using a 467 longitudinal study, a more extensive and rigorous longitudinal study was performed focusing on 468 the potential effect of LegH Prep on the estrous cycle. 469
28-Day Investigative Study in Rats with a 14-Day Pre-Dosing Estrous Cycle Determination 470
A 28-day dietary feeding study was performed with female rats to thoroughly evaluate 471 the estrous cycle stage distributions observed in the previous 28-day dietary feeding study. To 472 ensure all animals had normal estrous cyclicity prior to the 28-day dosing phase, estrous cycle 473 stage was determined daily for all animals for 14 days. Additionally, estrous cycle stage was 474 determined for all animals for the last 14 days of the 28-day dosing period. At study termination, 
Estrous cycle evaluation and Pathology 489
There were no test-substance-related changes in average estrus length attributable to 490 LegH Prep administration (Table 12 ). There were no macroscopic or microscopic findings 491 related to the administration of LegH Prep. A single Group 2 animal had prolonged estrus based 492 on morphology of the ovaries (large atretic follicles, multiple corpus lutea at a similar state of 493 atresia) and presence of squamous metaplasia of the uterus. These findings were considered 494 spontaneous and incidental due to the lack of similar findings at higher dose levels. One Group 1 495 animal had large atretic follicles observed in both ovaries, and one Group 4 animal had lutenized 496 follicles (follicles with evidence of lutenization in the wall but which have not ovulated) in both 497 ovaries. Both of these observations are reported as background findings in rats of the strain and 498 age used in this study 65 and were considered incidental because of their singular occurrences. 499
There were no test-substance-related changes in absolute or relative reproductive organ weight 500 values in female rats treated with LegH Prep (Table 13 ). Longitudinal daily monitoring of 501 estrous cycle stage demonstrated that, despite intrinsically normal estrous cycles, the distribution 502 of estrous cycle stages on any given day can be markedly different from the within-rat 503 distribution over time (Figure 1) . 504 505
Pathology Peer Review 506
Because there were no test-article-dependent effects observed in the estrous cycle study, 507 a pathology peer review was performed on the initial 28-day dietary feeding study. The review 508 pathologist evaluated histopathology in all female reproductive organs and corresponding 509 macroscopic and microscopic observations noted by the study pathologist. Following the peer 510 review, the study pathologist and review pathologist reached a consensus that there were no test-511 article-dependent effects on the female estrous cycle and reproductive organs. 512 513 Discussion 514 Heme is ubiquitous in the human diet and has been consumed for thousands of years. 515
Replacing the myoglobin that catalyzes the unique flavor chemistry of meat derived from 516 animals with LegH from soy opens an opportunity to develop plant-based meats that deliver to 517 consumers the pleasure they demand from animal-derived meats, with a small fraction of the 518 environmental impact. To evaluate the safety profile of soy leghemoglobin produced in Pichia, 519
we conducted a series of in vitro and in vivo studies. 520 To evaluate the in vivo safety profile for potential systemic toxicity, a 28-day feeding 531 study was conducted in rats in which LegH Prep was administered in the diet. Animals were 532 monitored for clinical observations, food consumption, body weight, ophthalmology, clinical 533 pathology, necropsy and histopathology. There were no LegH Prep-dependent effects observed 534 with the exception of a distinct estrous cycle stage distribution in Group 2 and 4 females at study 535 termination. Group 2 and 4 females had an increased incidence of the metestrus stage of the 536 estrous cycle, decreased presence of fluid filled uteri and dilated uterine lumens, and decreased 537 uterine weight compared to Group 1 and 3 females (Table 10-11). However, the correlation 538 between estrous cycle stage and reproductive organ weight and pathology for each animal was 539 consistent with published literature on normal healthy rats. 66 Therefore, although the estrous 540 cycle stage distribution was different between groups, there were no data to suggest an adverse 541 impact on the health of the female animals; the presence of both new and old ovarian corpora 542 lutea indicated normal estrous cyclicity. 65 were only monitored on a single day, a completely different conclusion would have been drawn 554 regarding the test article-effect on estrous cycle if the animals had been analyzed, for example, 555 on day 18 of the dosing period compared to day 21 ( Figure 1 ). The single day sampling artifact 556 readily accounts for the increased incidence of metestrus observed in the initial 28-day dietary 557 feeding study. Moreover, a pathology peer review of the original 28-day study resulted in a 558 consensus between the study pathologist and review pathologist that LegH Prep did not affect the 559 estrous cycle. 560
Together, these systemic toxicity and reproductive health feeding studies in rats 561 established a NOAEL of 750 mg/kg/day LegH for both sexes, which was the maximum dose 562 administered. Collectively these in vitro and in vivo results establish that LegH Prep, containing 563 both soy leghemoglobin protein and Pichia proteins from the production host, is safe for its 564 intended use in ground beef analogue products. 565
Creating safe, delicious plant-based meats to replace animal-derived meats in the diet is 566 critical to reducing and eventually eliminating the environmental impact of the animal farming 567 industry. Impossible Foods Inc. has shown that plant-based meat containing up to 0. 
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